AXNX News and Press, Axonics Modulation Technologies Inc. From 11/18/22

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will participate in the Piper Sandler Healthcare Conference on December 1, 2022. Axonics is scheduled to presen...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it ranked No. 4 on the Deloitte Technology Fast 500 , a ranking of the 500 fastest growing tech...

Axonics, Inc. (AXNX) Q3 2022 Earnings Conference Call October 31, 2022 16:30 ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Dan Dearen - President & Chief Financial Officer Conferenc...

Axonics Modulation Technologies press release ( NASDAQ: AXNX ): Q3 GAAP EPS of -$0.34 beats by $0.14 . Revenue of $70.4M (+50.1% Y/Y) beats by $7.42M . Sacral neuromodulation revenue was $56.9 million, of which $55.6 million was generated in the U.S. ...

Generated record quarterly revenue of $70 million, an increase of 50% year over year Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developi...

Axonics ( NASDAQ: AXNX ) is trading 5.6% lower after Needham downgraded rating to hold from buy. The analyst Mike Matson sees a less favorable risk/reward profile after Needham's urologist survey suggested the company may have difficulty driving upside to consensus 202...

Summary 100% technical buy signals. 7 new highs and up 5.40% in the last month. Analysts price targets from 70 to 95. The Chart of the Day belongs to the medical devices company Axonics ( AXNX ). I found the stock by sorting Barchart's All-Time High list firs...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the first patient implants in Canada with the Axonics F15™, the company’s newly devel...

Summary Axonics looks well-positioned to continue its recent upside on the chart, with a number of idiosyncratic tailwinds yet to be recognized. The recent equity underwriting of $35mm is noted, although this is hardly a risk given intended use for capital initiatives. Shares ...

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences: Event: We...